Pharmaceutical

Beacon secures $170m to advance ophthalmic gene therapies

Beacon’s lead candidate AGTC-501 is currently in a Phase II/III clinical trial for the treatment of X-linked retinitis pigmentosa (XLRP).

Jul 4, 2024 - 04:00
Beacon secures $170m to advance ophthalmic gene therapies
Beacon’s lead candidate AGTC-501 is currently in a Phase II/III clinical trial for the treatment of X-linked retinitis pigmentosa (XLRP).
Read the original article

Tags:

Previous Article

Mapping the surfaces of MXenes, atom by atom, reveals new potential for the 2D m...

Next Article

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: MD Anderson tried — and failed — to resolve research credit dispute between two scientists, new documents show

STAT+: MD Anderson tried — and failed — to resolve rese...

Feb 27, 2024

STAT+: Obama-era Medicare innovation initiative doesn’t save money after all

STAT+: Obama-era Medicare innovation initiative doesn’t...

Oct 2, 2023

Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

Recordati to acquire worldwide rights to Sanofi’s antib...

Oct 6, 2024